These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21761769)

  • 1. [The effect of the recombinant thrombomodulin which merged to hematological malignancy].
    Kawasugi K
    Rinsho Byori; 2011 Feb; Suppl 147():181-7. PubMed ID: 21761769
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thrombomodulin-relationship thrombotic marker and therapeutic effect].
    Nomura S
    Rinsho Byori; 2011 Feb; Suppl 147():188-93. PubMed ID: 21761770
    [No Abstract]   [Full Text] [Related]  

  • 3. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin.
    Ohshiro M; Kuroda J; Kobayashi Y; Akaogi T; Kawata E; Uoshima N; Kamitsuji Y; Kaneko H; Shimura K; Shimazaki C; Murakami S; Hatsuse M; Okano A; Kobayashi T; Uchiyama H; Matsumoto Y; Horiike S; Taniwaki M
    Am J Hematol; 2012 Jan; 87(1):116-9. PubMed ID: 21989545
    [No Abstract]   [Full Text] [Related]  

  • 4. [The efficacy of early use of recombinant soluble thrombomodulin for disseminated intravascular coagulation complicated with hematologic malignancies].
    Usami M; Kuroda H; Yoshida M; Sakamoto H; Shimoyama S; Kanari Y; Yamada M; Abe T; Fujii S; Maeda M
    Rinsho Ketsueki; 2015 Jun; 56(6):673-80. PubMed ID: 26256878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [How to use AT concentrate or recombinant thrombomodulin for the patients with sepsis analyzed by laboratory markers].
    Eguchi Y; Yoshida T; Okabe H
    Rinsho Byori; 2011 Feb; Suppl 147():213-5. PubMed ID: 21761775
    [No Abstract]   [Full Text] [Related]  

  • 6. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy.
    Nomura S; Fujita S; Ozasa R; Nakanishi T; Miyaji M; Mori S; Ito T; Ishii K
    Platelets; 2011; 22(5):396-7. PubMed ID: 21438846
    [No Abstract]   [Full Text] [Related]  

  • 7. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
    Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation.
    Ikezoe T; Takeuchi A; Chi S; Takaoka M; Anabuki K; Kim T; Sakai M; Taniguchi A; Togitani K; Yokoyama A
    Eur J Haematol; 2013 Nov; 91(5):442-7. PubMed ID: 23952647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin.
    Ogawa E; Yagasaki H; Kato M; Shichino H; Chin M; Mugishima H
    Br J Haematol; 2010 Jun; 149(6):911-2. PubMed ID: 20346017
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation.
    Maruyama I
    Thromb Haemost; 1999 Aug; 82(2):718-21. PubMed ID: 10605773
    [No Abstract]   [Full Text] [Related]  

  • 11. The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin.
    Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Thromb Res; 2019 Jan; 173():57-64. PubMed ID: 30472436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of recombinant human soluble thrombomodulin in patients with solid carcinoma with DIC].
    Asano Y; Kashiwagi S; Shibutani M; Yamazoe S; Noda S; Sakurai K; Nagahara H; Kimura K; Kawajiri H; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohtani H; Takashima T; Yashiro M; Onoda N; Maeda K; Ohira M; Hirakawa K
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2503-5. PubMed ID: 25731571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic malignant syndrome-induced massive coagulopathy treated by recombinant human soluble thrombomodulin.
    Hayashida K; Fujishima S; Nakaya N; Abe S; Shiroshita-Takeshita A; Hori S
    Am J Emerg Med; 2013 Mar; 31(3):636.e1-3. PubMed ID: 23218866
    [No Abstract]   [Full Text] [Related]  

  • 14. [Successful treatment using recombinant thrombomodulin for disseminated intravascular coagulation associated with recurrent prosthetic valve endocarditis].
    Masuda S; Adachi O; Ito K; Matsuo S; Hayatsu Y; Suzuki Y; Saito T; Akiyama M; Kumagai K; Motoyoshi N; Kawamoto S; Saiki Y
    Kyobu Geka; 2013 Feb; 66(2):101-5. PubMed ID: 23381354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of recombinant thrombomodulin in septic patients].
    Eguchi Y
    Rinsho Byori; 2011 Feb; Suppl 147():177-80. PubMed ID: 21761768
    [No Abstract]   [Full Text] [Related]  

  • 16. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan".
    Wada H; ; Okamoto K; Iba T; Kushimoto S; Kawasugi K; Gando S; Madoiwa S; Uchiyama T; Mayumi T; Seki Y
    Thromb Res; 2014 Oct; 134(4):924-5. PubMed ID: 25135793
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
    J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects.
    Tsuruta K; Yamada Y; Serada M; Tanigawara Y
    J Clin Pharmacol; 2011 Sep; 51(9):1276-85. PubMed ID: 21098690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombosis and DIC in hematological malignancies].
    Asakura H
    Rinsho Ketsueki; 2014 Oct; 55(10):2066-75. PubMed ID: 25297773
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experience in the treatment with recombinant thrombomodulin on disseminated intravascular coagulation with severe urinary tract infection].
    Fumino M; Kurimoto K; Kinoshita N; Kato H; Arima K; Sugimura Y
    Hinyokika Kiyo; 2012 Feb; 58(2):71-4. PubMed ID: 22450831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.